Examkin

Question

Difficulty: HardConflicts of Interest

A 50-year-old rheumatologist at an academic medical center is the principal investigator for a phase 3 clinical trial evaluating a novel biologic agent for systemic lupus erythematosus. Patient enrollment has been slower than expected. To accelerate recruitment, the pharmaceutical company sponsoring the trial offers the physician a $1,000 "finder's fee" for each patient successfully enrolled. This fee is in addition to the standard, fair-market-value compensation already provided for the clinical and administrative time spent conducting the study. The physician plans to use these additional funds entirely to purchase new infusion chairs for the clinic, which will benefit all patients. Which of the following is the most appropriate action for the physician regarding this offer?

  1. A
    Accept the finder's fee, provided the arrangement is formally submitted to the state health department under mandatory reporting laws.
  2. B
    Accept the finder's fee, because directing the funds toward patient care resources resolves the underlying ethical conflict.
  3. Decline the finder's fee, as research compensation must solely reflect fair market value for the time and effort expended.Answer
  4. D
    Petition a judge to evaluate the patient's legal competence before obtaining consent for an incentivized trial.
  5. E
    Decline the cash fee, but negotiate for the sponsor to directly donate the equipment in exchange for meeting enrollment targets.

Answer

The physician must decline the finder's fee because compensation for clinical research must only reflect the fair market value of the time and effort spent conducting the study.
The correct answer identifies that the physician must decline the finder's fee. According to the American Medical Association (AMA) Code of Medical Ethics, physicians participating in clinical research should only receive compensation that is commensurate with the fair market value of their actual time and effort. Accepting "finder's fees" or any compensation tied directly to the number of patients enrolled creates a severe financial conflict of interest. This arrangement introduces an unethical incentive that could bias the physician's clinical judgment, potentially compromising patient safety, informed consent, and the scientific integrity of the trial. The fact that the physician plans to use the funds altruistically to purchase clinic equipment does not mitigate this structural conflict.

Step-by-Step Solution

1
Identify the core ethical dilemma presented in the scenario.
The physician is being offered a per-patient financial bonus (finder's fee) for enrolling subjects into a clinical trial.
Recognizing the nature of the financial incentive is required to evaluate it against ethical standards.
2
Apply the AMA Code of Medical Ethics guidelines regarding clinical research compensation.
Physicians may only accept compensation that represents fair market value for the actual clinical and administrative time and effort expended.
Finder's fees or volume-based enrollment bonuses are strictly prohibited because they create an incentive to prioritize recruitment over patient safety and suitability.
3
Evaluate the physician's plan to use the funds for clinic equipment (infusion chairs).
The altruistic destination of the funds does not mitigate the structural conflict of interest.
The financial incentive still exists and risks subconsciously or consciously biasing the physician's clinical judgment during the consent and enrollment process.
4
Determine the appropriate course of action.
The physician must decline the finder's fee and any equivalent volume-based gifts.
Maintaining professional boundaries and research integrity requires rejecting unethical compensation structures.

Key Concept

Physicians are strictly prohibited from accepting finder's fees or per-capita bonuses for enrolling patients in clinical trials. All research compensation must be commensurate with the fair market value of the time and effort expended.
Estimated Time:1m 30s
Rate this question

Topics

Conflicts of Interest

More questions from this topic